Developments in depression in epilepsy: screening, diagnosis, and treatment.

Area of Science:

• Neurology
• Psychiatry
• Clinical Medicine

Background:

• Depression is a common comorbidity in epilepsy, affecting 17-22% of patients.
• It remains underdiagnosed and undertreated in this population.
• Clinical scenarios for depression in epilepsy are heterogeneous.

Purpose of the Study:

• To discuss recent advances in screening, diagnosis, and treatment of depression in epilepsy.
• To highlight validated screening instruments and challenges in diagnosis.
• To review current treatment options and evidence levels.

Main Methods:

• Review of recent advances in depression screening, diagnosis, and treatment in epilepsy.
• Discussion of validated screening instruments, including the Neuropsychiatric Inventory-Depression and Anxiety subscales (NDDI-E).
• Analysis of diagnostic challenges and treatment evidence.

Main Results:

• Several screening instruments are validated for adults with epilepsy; the NDDI-E is considered practical and cost-effective.
• Atypical features of mood disorders in epilepsy present diagnostic challenges.
• Psychological treatments and SSRIs are indicated, but evidence levels are low.

Conclusions:

• Epilepsy centers require defined care pathways for depression to ensure access to mental health support.
• Further rigorous studies are needed to establish proper outcome measures for depression treatment in epilepsy.
• Improved screening and diagnosis are crucial for better management of depression in epilepsy patients.